Image For Activity Cover
2023 Targeted Therapies of Lung Cancer Meeting (Poster)
Conference | 2023
What's Included
P1.01. Changes in PD-L1 Expression and Tumor Mutational Burden Between Paired Samples and Relationship to Immune Checkpoint Inhibitor Outcomes in Patients with Non-Small Cell Lung Cancer
Faculty:
- Alessandro Di Federico, Dana-Farber Cancer Institute, United States

P1.02. MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC): An Analysis by Specific Mutation, Histology, and Smoking Status
Faculty:
- Jennifer A. Marks, Georgetown University, United States

P1.03. Lung Cancer Approved Tyrosine Kinase Inhibitors That Inhibit MATE-1 can Lead to “False” Decreases in Renal Function
Faculty:
- Monica Chen, MSKCC, United States

P1.04. Impact of STK11 and/or KEAP1 Deletion on Outcomes to Immunotherapy in Non-Small Cell Lung Cancer
Faculty:
- Malini Gandhi, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, United States

P1.05. Genomic And Immunophenotypic Landscape Of Acquired Resistance (AR) To PD-(L)1 Blockade In Non-Small Cell Lung Cancer
Faculty:
- Biagio Ricciuti, Dana-Farber Cancer Institute, United States

P1.06. Real World Outcomes of Lurbinectedin as Second Line Treatment in Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
Faculty:
- Aakash Desai, Mayo Clinic, United States

P1.07. Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-Mutant Lung Cancer
Faculty:
- Paul Stockhammer, Yale School of Medicine, United States

P1.08. Pivotal Data Update from the Phase 1/2 TRIDENT-1 Trial of Repotrectinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer (NSCLC)
Faculty:
- Guilherme Harada, Memorial Sloan Kettering Cancer Center, United States

P1.09. Activating MET Kinase Domain Mutations Define a Novel Targetable Molecular Subtype of Non-Small Cell Lung Cancer That is Clinically Sensitive to MET Inhibitor Elzovantinib (TPX-0022)
Faculty:
- Federica Pecci, Lowe Center for Thoracic Oncology, Dana-farber Cancer Institute, United States

P1.10. Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in Non-small Cell Lung Cancer
Faculty:
- Joao Alessi, Dana-Farber Cancer Institute, United States

P1.11. A Phase 1 Trial of BI 1810631, a HER2 Tyrosine Kinase Inhibitor (TKI), as Monotherapy in Patients with Advanced/Metastatic Solid Tumors with HER2 Aberrations
Faculty:
- Hibiki Udagawa, The University of Texas MD Anderson Cancer Center, United States

P1.12. Activity of Gilteritinib in Resistant ROS1 Rearranged Non-Small Cell Lung Cancer
Faculty:
- Rajat Thawani, Oregon Health & Science University, United States

P1.13. MDM2 Inhibition in Combination with MEK Inhibition in Pre-clinical Models of Lung Adenocarcinomas with MDM2 Amplification
Faculty:
- Arielle Elkrief, Memorial Sloan Kettering Cancer Center, United States

P1.14. Differentiating Ensartinib from Lorlatinib and Alectinib for First Line Use in an ALK+ Non-Small Cell Lung Cancer Preclinical Model (ResCu)
Faculty:
- Christopher Bulow, ResistanceBio, United States

P1.15. Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer by Prior Line of Systemic Therapy and Performance Status
Faculty:
- Matteo Repetto, Memorial Sloan Kettering Cancer Center, United States

P1.16. Targetable Molecular Algorithm and Training Pathways Development for Treatment of the Non-Small Cell Lung Cancer
Faculty:
- Ayesha Munir, Medstar Georgetown Cancer Institute, United States

P1.17. Clinical and Genomic Predictors of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients with Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Faculty:
- Rohit Thummalapalli, Memorial Sloan Kettering Cancer Center, United States

P1.18. Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer
Faculty:
- Jacqueline Aredo, Stanford Cancer Institute, United States

P1.19. IDH1 and IDH2 Mutations in Non-small Cell Lung Cancer (NSCLC)
Faculty:
- Lacey Williams, Georgetown University, United States

P1.20. Prognostic and Predictive Relevance of 3q Amplification in Squamous Cell Carcinoma of the Lung
Faculty:
- Fawzi Abu Rous, Henry Ford Health, United States

P1.21. HER2/ERBB2 Mutations in Metastatic Non-Small Cell Lung Cancer – Prevalence, Real-World Treatment Patterns and Outcomes from a Clinico-Genomic Database
Faculty:
- Sarah Waliany, Stanford University School of Medicine, United States

P1.22. Mutations in Spliceosome Genes, SRSF2 and FUBP1, in NSCLC Are Associated with Multiple Actionable Driver Mutations, Notably KRAS G12C/V and EGFR L858R as Well as STK11/KEAP1 Mutations without Actionable Driver Mutations. Results Collected from a Survey of cBioPortal GENIE Database
Faculty:
- Alexandria Lee, University of California Irvine School of Medicine Department of Internal Medicine, United States

P1.23. Mutations in the RNA Binding Motif Protein 10 (RMB10) in NSCLC Are Highly Associated with Multiple Actionable Driver Mutatio
Faculty:
- Danielle Brazel, University of California Irvine, United States

P1.24. Plasma PCSK9 Levels in Patients Receiving Neoadjuvant Pembrolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC)
Faculty:
- Cameron Wood, Duke University Health System, United States

P1.25. Fibroblast Growth Factor Receptor (FGFR) Aberrations in Metastatic Non-Small Cell Lung Cancer (mNSCLC): An Analysis of Prevalence and a Potential Therapeutic Target for Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs)
Faculty:
- Karan Jatwani, Roswell Park Comprehensive Cancer Center, United States

P1.26. Out of Pocket Costs and Receipt of Financial Assistance for Patients with Lung Cancer Prescribed an Oral Targeted Therapy at an Academic Medical Center
Faculty:
- Meera Ragavan, University of California, San Francisco, United States

P1.27. Clinicogenomic Characteristics of EGFR-Mutant Non-Small Cell Lung Carcinoma with CNS Metastases
Faculty:
- Jane Sze Yin Sui, Memorial Sloan Kettering Cancer Center, United States

P1.28. Inhibition of ATR Can Target Osimertinib Resistance in EGFR-Mutated NSCLC
Faculty:
- Benjamin Herzberg, Columbia University Medical Center, United States

P1.29. The LAG-3/FGL1 Axis is a Dominant Immune Evasion Pathway in NSCLC Modulated by Hypoxia
Faculty:
- Maria Villalba Esparza, Yale University, United States

P1.30. NRG1 Fusions in Non-Small Cell Lung Cancer (NSCLC)
Faculty:
- Muneeb Rehman, Georgetown University, United States

P1.31. GUK1 is a Novel Metabolic Liability in Oncogene-Driven Lung Cancer
Faculty:
- Jaime Schneider, Massachusetts General Hospital, United States

P1.32. Durable Complete Response in Leptomeningeal Disease (LMD) of EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) to Amivantamab, an EGFR-MET Receptor Bispecific Antibody, After Progressing on Osimertinib
Faculty:
- Yoonhee Choi, New York-Presbyterian of Queens, United States

P1.3. SMARCA4-deficient Undifferentiated Lung Carcinoma with Additional Microsatellite Instability Mixed Response to Pembrolizumab Followed by Hyperprogression – A Cautionary Tale Highlighting the Pitfalls to Tumor Agnostic Drug Approvals
Faculty:
- Elizabeth Burns, University of Florida, United States

P1.34. BASECAMP-1: Leveraging Human Leukocyte Antigen A (HLA-A) Loss of Heterozygosity (LOH) in Solid Tumors by Next-Generation Sequencing (NGS) to Identify Patients With Relapsed Solid Tumors for Carcinoembryonic Antigen (CEA) and Mesothelin (MSLN) Logic-Gated
Faculty:
- Caleb Smith, Mayo Clinic, United States

P1.35. A Case and the Landscape of Coexisting EGFR Mutation in Non-Small Cell Lung Cancer (NSCLC) with Microsatellite Instability (MSI) High and Tumor Mutation Burden (TMB) High Traits
Faculty:
- Leeseul Kim, Ascension Saint Francis Hospital, United States

Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Contains (34)
P1.01. Changes in PD-L1 Expression and Tumor Mutational Burden Between Paired Samples and Relationship to Immune Checkpoint Inhibitor Outcomes in Patients with Non-Small Cell Lung Cancer
P1.02. MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC): An Analysis by Specific Mutation, Histology, and Smoking Status
P1.03. Lung Cancer Approved Tyrosine Kinase Inhibitors That Inhibit MATE-1 can Lead to “False” Decreases in Renal Function
P1.04. Impact of STK11 and/or KEAP1 Deletion on Outcomes to Immunotherapy in Non-Small Cell Lung Cancer
P1.05. Genomic And Immunophenotypic Landscape Of Acquired Resistance (AR) To PD-(L)1 Blockade In Non-Small Cell Lung Cancer
P1.06. Real World Outcomes of Lurbinectedin as Second Line Treatment in Extensive Stage-Small Cell Lung Cancer (ES-SCLC)
P1.07. Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-Mutant Lung Cancer
P1.08. Pivotal Data Update from the Phase 1/2 TRIDENT-1 Trial of Repotrectinib in Patients with ROS1+ Advanced Non-Small Cell Lung Cancer (NSCLC)
P1.09. Activating MET Kinase Domain Mutations Define a Novel Targetable Molecular Subtype of Non-Small Cell Lung Cancer That is Clinically Sensitive to MET Inhibitor Elzovantinib (TPX-0022)
P1.10. Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in Non-small Cell Lung Cancer
P1.11. A Phase 1 Trial of BI 1810631, a HER2 Tyrosine Kinase Inhibitor (TKI), as Monotherapy in Patients with Advanced/Metastatic Solid Tumors with HER2 Aberrations
P1.12. Activity of Gilteritinib in Resistant ROS1 Rearranged Non-Small Cell Lung Cancer
P1.13. MDM2 Inhibition in Combination with MEK Inhibition in Pre-clinical Models of Lung Adenocarcinomas with MDM2 Amplification
P1.14. Differentiating Ensartinib from Lorlatinib and Alectinib for First Line Use in an ALK+ Non-Small Cell Lung Cancer Preclinical Model (ResCu)
P1.15. Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase (TRK) Fusion Lung Cancer by Prior Line of Systemic Therapy and Performance Status
P1.16. Targetable Molecular Algorithm and Training Pathways Development for Treatment of the Non-Small Cell Lung Cancer
P1.17. Clinical and Genomic Predictors of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients with Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
P1.18. Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer
P1.19. IDH1 and IDH2 Mutations in Non-small Cell Lung Cancer (NSCLC)
P1.20. Prognostic and Predictive Relevance of 3q Amplification in Squamous Cell Carcinoma of the Lung
P1.21. HER2/ERBB2 Mutations in Metastatic Non-Small Cell Lung Cancer – Prevalence, Real-World Treatment Patterns and Outcomes from a Clinico-Genomic Database
P1.22. Mutations in Spliceosome Genes, SRSF2 and FUBP1, in NSCLC Are Associated with Multiple Actionable Driver Mutations, Notably KRAS G12C/V and EGFR L858R as Well as STK11/KEAP1 Mutations without Actionable Driver Mutations. Results Collected from a Survey of cBioPortal GENIE Database
P1.23. Mutations in the RNA Binding Motif Protein 10 (RMB10) in NSCLC Are Highly Associated with Multiple Actionable Driver Mutatio
P1.24. Plasma PCSK9 Levels in Patients Receiving Neoadjuvant Pembrolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC)
P1.26. Out of Pocket Costs and Receipt of Financial Assistance for Patients with Lung Cancer Prescribed an Oral Targeted Therapy at an Academic Medical Center
P1.27. Clinicogenomic Characteristics of EGFR-Mutant Non-Small Cell Lung Carcinoma with CNS Metastases
P1.28. Inhibition of ATR Can Target Osimertinib Resistance in EGFR-Mutated NSCLC
P1.29. The LAG-3/FGL1 Axis is a Dominant Immune Evasion Pathway in NSCLC Modulated by Hypoxia
P1.30. NRG1 Fusions in Non-Small Cell Lung Cancer (NSCLC)
P1.31. GUK1 is a Novel Metabolic Liability in Oncogene-Driven Lung Cancer
P1.32. Durable Complete Response in Leptomeningeal Disease (LMD) of EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) to Amivantamab, an EGFR-MET Receptor Bispecific Antibody, After Progressing on Osimertinib
P1.34. BASECAMP-1: Leveraging Human Leukocyte Antigen A (HLA-A) Loss of Heterozygosity (LOH) in Solid Tumors by Next-Generation Sequencing (NGS) to Identify Patients With Relapsed Solid Tumors for Carcinoembryonic Antigen (CEA) and Mesothelin (MSLN) Logic-Gated
P1.35. A Case and the Landscape of Coexisting EGFR Mutation in Non-Small Cell Lung Cancer (NSCLC) with Microsatellite Instability (MSI) High and Tumor Mutation Burden (TMB) High Traits
P1.18. Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS Mutant Non-Small Cell Lung Cancer - 2
Powered By